Friday 6 November 2026 Export UTHR’s income statement to Excel — free account

United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.

Revenue: +4.13%
EPS: −21.7%
Free cash flow: −63.7%

Quarter to September 2026, against a year earlier

564.88 43.61 −7.17%

Follow UTHR

Alert me

Market cap: $24.3B
P/E: 19.7×
Fwd P/E: 22.5×
Dividend yield: —
F-score: 8/9
Altman Z: 19.55
Beneish M: −2.26
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

United Therapeutics Corporation (UTHR) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, United Therapeutics Corporation (UTHR) trades at a P/S ratio of 7.6×. Over the past ten years it has ranged from 2.1× (June 2019) to 8.2× (May 2026); the current reading is higher than 98% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/UTHR/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="United Therapeutics Corporation P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/UTHR/metrics/ps-ratio">United Therapeutics Corporation (UTHR) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	6.8×	22.36%
FY2024	5.5×	21.25%
FY2023	4.6×	(28.82%)
FY2022	6.4×	11.58%
FY2021	5.8×	27.26%
FY2020	4.5×	69.86%
FY2019	2.7×	(8.50%)
FY2018	2.9×	(24.90%)
FY2017	3.9×	(1.77%)
FY2016	3.9×	(19.74%)

Period	P/S ratio	Change
Sep 2026	7.3×	(0.79%)
Jun 2026	7.3×	(10.08%)
Mar 2026	8.1×	19.99%
Dec 2025	6.8×	15.55%
43 more quarters	Free account

Against its own ten years

Low 2.1× High 8.2×

Ten-year median 4.7×

Current reading's percentile 98

Company	P/S ratio
VTRS Viatris Inc. compare	1.5×
TAK Takeda Pharmaceutical Co. compare	2.2×
HLN Haleon PLC Sponsored ADR compare	2.3×
ELAN Elanco Animal Health Incorporated compare	2.4×
TEVA Teva Pharmaceutical Industries Ltd. compare	2.8×
ZTS Zoetis Inc. compare	3.6×
RDY Dr. Reddy's Laboratories Ltd compare	3.6×
NBIX Neurocrine Biosciences, Inc. compare	4.4×
UTHR United Therapeutics Corporation	7.6×
Drug Manufacturers Specialty & Generic industry median	2.1×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

United Therapeutics Corporation (UTHR) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on UTHR

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on UTHR

Stockrow Weekly